Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine Among Actively Treated Cancer Patients.
Journal
Journal of the National Cancer Institute
ISSN: 1460-2105
Titre abrégé: J Natl Cancer Inst
Pays: United States
ID NLM: 7503089
Informations de publication
Date de publication:
07 Feb 2022
07 Feb 2022
Historique:
received:
22
05
2021
revised:
06
07
2021
accepted:
26
08
2021
pubmed:
29
8
2021
medline:
12
2
2022
entrez:
28
8
2021
Statut:
ppublish
Résumé
Activity and safety of the SARS-CoV-2 BNT162b2 vaccine in actively treated patients with solid tumors is currently unknown. We conducted a retrospective study of 326 patients with solid tumors treated with anticancer medications to determine the proportion of cancer patients with immunogenicity against SARS-CoV-2 following 2 doses of the BNT162b2 vaccine. The control group comprised 164 vaccinated healthy adults. Anti-SARS-CoV-2 S immunoglobulin G antibodies were measured using a level greater than 50 AU/mL as a cutoff for seropositivity. Information on adverse effects was collected using a questionnaire. All statistical tests were 2-sided. Most patients (205, 62.9%) were treated with chemotherapy either alone or with additional therapy; 55 (16.9%) were treated with immune checkpoint inhibitors and 38 (11.7%) with targeted therapy alone; 28 (8.6%) received other combinations. The vaccine was well tolerated, and no severe side effects were reported. Among patients with cancer, 39 (11.9%) were seronegative compared with 5 (3.0%) of the control group (P = .001). Median immunoglobulin G titers were statistically significantly lower among patients with cancer compared with control (931 AU/mL vs 2817 AU/mL, P = .003). Seronegativity proportions were higher in the chemotherapy-treated group (n = 19; 18.8%) compared with the immune checkpoint inhibitor-treated patients (n = 5; 9.1%) and with those treated with targeted therapy (n = 1; 2.6%) (P = .02). Titers were also statistically significantly different among treatment types (P = .002). The BNT162b2 vaccine is safe and effective in actively treated patients with cancer. The relatively lower antibody titers and lower proportion of seropositive patients, especially among chemotherapy-treated patients, call for continuing the use of personal protective measures in these patients, even following vaccination.
Sections du résumé
BACKGROUND
BACKGROUND
Activity and safety of the SARS-CoV-2 BNT162b2 vaccine in actively treated patients with solid tumors is currently unknown.
METHODS
METHODS
We conducted a retrospective study of 326 patients with solid tumors treated with anticancer medications to determine the proportion of cancer patients with immunogenicity against SARS-CoV-2 following 2 doses of the BNT162b2 vaccine. The control group comprised 164 vaccinated healthy adults. Anti-SARS-CoV-2 S immunoglobulin G antibodies were measured using a level greater than 50 AU/mL as a cutoff for seropositivity. Information on adverse effects was collected using a questionnaire. All statistical tests were 2-sided.
RESULTS
RESULTS
Most patients (205, 62.9%) were treated with chemotherapy either alone or with additional therapy; 55 (16.9%) were treated with immune checkpoint inhibitors and 38 (11.7%) with targeted therapy alone; 28 (8.6%) received other combinations. The vaccine was well tolerated, and no severe side effects were reported. Among patients with cancer, 39 (11.9%) were seronegative compared with 5 (3.0%) of the control group (P = .001). Median immunoglobulin G titers were statistically significantly lower among patients with cancer compared with control (931 AU/mL vs 2817 AU/mL, P = .003). Seronegativity proportions were higher in the chemotherapy-treated group (n = 19; 18.8%) compared with the immune checkpoint inhibitor-treated patients (n = 5; 9.1%) and with those treated with targeted therapy (n = 1; 2.6%) (P = .02). Titers were also statistically significantly different among treatment types (P = .002).
CONCLUSIONS
CONCLUSIONS
The BNT162b2 vaccine is safe and effective in actively treated patients with cancer. The relatively lower antibody titers and lower proportion of seropositive patients, especially among chemotherapy-treated patients, call for continuing the use of personal protective measures in these patients, even following vaccination.
Identifiants
pubmed: 34453830
pii: 6359210
doi: 10.1093/jnci/djab174
pmc: PMC8499747
doi:
Substances chimiques
Antibodies, Viral
0
COVID-19 Vaccines
0
RNA, Messenger
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
203-209Commentaires et corrections
Type : CommentIn
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Références
Cancer Discov. 2020 Jun;10(6):783-791
pubmed: 32345594
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
Sci Adv. 2021 Mar 19;7(12):
pubmed: 33608249
N Engl J Med. 2021 Apr 15;384(15):1412-1423
pubmed: 33626250
Blood. 2021 Jul 1;137(26):3674-3676
pubmed: 33861315
Ann Oncol. 2021 Aug;32(8):1053-1055
pubmed: 33932508
Lancet Oncol. 2021 May;22(5):581-583
pubmed: 33812495
J Clin Microbiol. 2021 Jun 18;59(7):e0038821
pubmed: 33827901
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Clin J Am Soc Nephrol. 2021 Jul;16(7):1037-1042
pubmed: 33824157
Lancet Oncol. 2021 Jun;22(6):765-778
pubmed: 33930323
Ann Oncol. 2011 Sep;22(9):2031-2035
pubmed: 21303799
Blood. 2021 Jun 10;137(23):3165-3173
pubmed: 33861303
JAMA. 2021 May 4;325(17):1784-1786
pubmed: 33720292
N Engl J Med. 2020 Dec 17;383(25):2439-2450
pubmed: 33053279
Lancet. 2020 Jun 20;395(10241):1919-1926
pubmed: 32473682
Nature. 2020 Oct;586(7830):594-599
pubmed: 32998157
N Engl J Med. 2021 Jan 7;384(1):80-82
pubmed: 33270381
JAMA. 2021 Jun 1;325(21):2204-2206
pubmed: 33950155